Grotz 2001.

Methods	Study design: parallel RCT Duration of study: not reported Duration of follow‐up: 12 months
Participants	Country: Germany Setting: single centre Inclusion criteria: patients aged 20 to 60 years awaiting transplantation Number: treatment group (36); control group (36) Mean age ± SD (years): treatment group (42 ± 10); control group (44 ± 10) Sex (M/F): treatment group (25/11); control group (23/13) Diabetes: treatment group (1/36); control group (1/36) Exclusion criteria: combined kidney‐pancreas transplantation
Interventions	Treatment group Ibandronate: 1 mg immediately before transplantation and 2 mg at 3, 6, and 9 months Control group No treatment Co‐interventions Not reported
Outcomes	Biochemical parameters (calcium, phosphate, creatinine) BMD of femoral neck, lumbar spine and forearm by DEXA
Notes	Funding source: not reported Trial registration: not applicable as published before end of 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All X‐rays were evaluated by a radiologist who was blinded to the randomisation
Incomplete outcome data (attrition bias) All outcomes	Low risk	8/80 patients did not complete the study with equal numbers in each group
Selective reporting (reporting bias)	Low risk	Patient‐centred outcomes including graft function were reported
Other bias	Low risk	No additional threats to validity identified